KLRK1 and acute myeloid leukemia: NKG2D ligands are also being targeted by Nkarta using allogeneic CAR-engineered NK cells, administered to patients with AML (https://ir.nkartatx.com/news-releases/news-release-details/nkarta-announces-positive-preliminary-dose-finding-data-two-lead, accessed on 14 December 2022).